Lipe & Dalton’s Amedisys AMED Stock Holding History

Lipe & Dalton’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-22,952	Closed	-$2.22M	–	100
2022 Q3	$2.22M	Buy	22,952 +150	+0.7%	+$17.9K	1.39%	23
2022 Q2	$2.4M	Hold	22,802	–	–	1.4%	24
2022 Q1	$3.93M	Buy	+22,802	New	+$3.41M	1.92%	20

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Lipe & Dalton's AMED Position: Q4 2022 in Review

Lipe & Dalton sold out of Amedisys (AMED) in Q4 2022, closing a stake of 22,952 shares — an estimated $2.22M sold.

Lipe & Dalton first reported a position in AMED in Q1 2022 and held it in 3 quarters. The position peaked at $3.93M in Q1 2022. 277 funds tracked by Wall St. Rank hold AMED as of Q4 2022.

Lipe & Dalton reported no remaining Amedisys position as of Q4 2022 after selling out during the quarter.
Lipe & Dalton sold 22,952 Amedisys shares in Q4 2022, an estimated $2.22M.
Lipe & Dalton first reported a position in Amedisys in Q1 2022 and held it in 3 quarters.
Lipe & Dalton's Amedisys position peaked at $3.93M in Q1 2022.
277 funds tracked by Wall St. Rank held Amedisys as of Q4 2022.

Based on Lipe & Dalton's 13F filing for Q4 2022, filed 3 Feb 2023.